Top Markets
Coin of the day
Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc.

9960
주식 순위 #20802
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly... Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.
주가
$0.11897139
시가총액
$122.93M
변동 (1일)
0.54%
변동 (1년)
-44.66%
국가
CN
거래 Kindstar Globalgene Technology, Inc. (9960)

카테고리

Kindstar Globalgene Technology, Inc. (9960)의 수익
2026 기준 수익 TTM: 0
Kindstar Globalgene Technology, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Kindstar Globalgene Technology, Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.58B -
US